In our current mini-series exploring emerging biotech companies with early pipelines and novel targets, we investigate some interesting approaches that are not common place.  As large cap Pharmaland companies seem overly focused on hunting for the next checkpoint target, smaller biotechs are more nimbly coming up with some fresh ideas that might have solid merit down the road.

All aboard!

This is one of those such innovative companies.

What if there was a different approach where we can learn from the immune system’s response to a cancer?  Sounds obvious and intuitive when put so baldly, yet few companies are actually doing that in practice.

What would such a process and pipeline look like?

Come and find out for yourselves – you may well be surprised because some ideas that seem crazy at first blush, could turn out to be rather useful indeed…

To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by